Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics

Rhea-AI Summary

Bicycle Therapeutics plc (NASDAQ: BCYC) announced the publication of preclinical data for BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, in Molecular Cancer Therapeutics. The article details its efficacy in killing solid tumor cells, with significant tumor regression observed in various models. The results follow positive interim findings from its Phase I trial, which suggest BT8009's potential for treating solid tumors effectively. Additional clinical data is expected later this year, underscoring the drug’s promising development trajectory.

Positive

• Publication of preclinical data for BT8009 in a reputable journal.
• Positive interim results reported from the ongoing Phase I trial.
• Full tumor regression observed in both large and small tumor models.

Negative

• None.

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics. The article, titled “BT8009: a Nectin-4 targeting Bicycle® Toxin Conjugate for treatment of solid tumors” is available online via this link.

“Having already announced interim, positive results from our ongoing Phase I trial of BT8009, we are pleased to describe the work leading to its identification and the preclinical studies that support its potential to rapidly diffuse into, and to kill, solid tumor cells.” said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “The data published in Molecular Cancer Therapeutics describe BT8009’s pre-clinical efficacy in a wide range of cell-derived xenograft and patient-derived xenograft tumor models, with full tumor regression frequently seen in large and small tumors. We look forward to providing additional clinical data on BT8009 later this year.”

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the clinical development of BT8009 and Bicycle’s expectations regarding the availability of additional clinical data from the ongoing Phase I/II clinical trial of BT8009; and the potential of BT8009 to diffuse into solid tumors and kill solid tumor cells. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; availability and timing of results from clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005691/en/

Investors:

David Borah, CFA

VP, Capital Markets & Investor Relations

david.borah@bicycletx.com

617-203-8300

Media:

Argot Partners

Sarah Sutton

bicycle@argotpartners.com

212-600-1902

Source: Bicycle Therapeutics plc

FAQ

What is the significance of the BT8009 study for Bicycle Therapeutics (BCYC)?

The BT8009 study highlights its preclinical efficacy against solid tumors, suggesting its potential as a new treatment option.

When can we expect additional clinical data for BT8009?

Bicycle Therapeutics expects to provide additional clinical data later this year.

What does the publication in Molecular Cancer Therapeutics indicate about BT8009?

The publication indicates strong preclinical support and credibility for BT8009's development as a therapeutic agent against solid tumors.

What type of technology does Bicycle Therapeutics use for its drug development?

Bicycle Therapeutics specializes in developing Bicycles, which are synthetic peptides designed to target diseases with high affinity.